Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,16
KB-0,67
PKN84,3684,38-0,06
Msft496,67496,7-0,43
Nokia4,314,4990,93
IBM291,64291,7-0,09
Mercedes-Benz Group AG49,8749,88-0,36
PFE25,225,21-0,69
07.07.2025 21:28:53
Indexy online
AD Index online
select
AD Index online
 

  • 07.07.2025 21:28:53
Aurinia Pharma (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
7,46 -1,78 -0,14 975 636
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 07.07.2025
Popis společnosti
Obecné informace
Název společnostiAurinia Pharmaceuticals Inc
TickerAUPH
Kmenové akcie:Ordinary Shares
RICAUPH.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2023 300
Akcie v oběhu k 08.05.2025 135 104 302
MěnaUSD
Kontaktní informace
Ulice#140, 14315 - 118 AVENUE
MěstoEDMONTON
PSČT5L 4S6
ZeměCanada
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 507 442 487
Fax12507084345

Business Summary: Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Aurinia Pharmaceuticals Inc revenues increased 24% to $62.5M. Net income totaled $23.3M vs. loss of $10.7M. Revenues reflect Net product sales increase of 25% to $60M, Revenue Sales of Goods & Services increase of 12% to $2.5M. Net Income reflects Stock-based Compensation in SGA decrease from $7.5M (expense) to $3.5M (income), Labor & Related Expenses in SGA decrease of 44% to $12.1M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 07.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorPeter Greenleaf5529.04.201929.04.2019
Chief Financial OfficerJoseph Miller5127.04.202027.04.2020
Chief Operating OfficerMatthew Donley5615.07.2019
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate SecretaryStephen Robertson4320.11.202020.11.2020
Chief Medical OfficerGreg Keenan6427.02.202327.02.2023